TALVEY (talquetamab) Patient Assistance Program
Don’t let the high cost of brand specialty multiple myeloma bispecific therapy stand between you and the treatment you need. We help eligible patients access Talvey (talquetamab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Talvey (talquetamab) is FDA-approved for the treatment of relapsed or refractory multiple myeloma in adults who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. It is given as a subcutaneous injection.
- Without assistance, the retail cost commonly runs $30,000–$45,000 per month at standard maintenance dosing, with annual treatment costs commonly reaching $400,000+.
- Through AffordMyPrescriptions, qualifying patients can access Talvey for a flat $69.95 per month — our advocacy team manages the entire enrollment, injections, and renewal process.
- There is no biosimilar version of Talvey available in the U.S. as of 2026. Talvey is dispensed through limited specialty pharmacy distribution, and treatment requires REMS-program enrollment due to cytokine release syndrome and neurotoxicity risks.
What Is Talvey Prescription Assistance Program?
The Talvey Prescription Assistance Program is a manufacturer-sponsored initiative that provides Talvey at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for relapsed/refractory multiple myeloma patients who are uninsured or underinsured, as well as Medicare beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology-team coordination, prior-treatment documentation, REMS-program enrollment, hospital-based step-up dosing coordination, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing injection-schedule coordination and annual re-certification — so you focus on your treatment, not paperwork.
Pharmacy Price Comparison
- Without assistance, Talvey costs roughly $30,000–$45,000 per month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Step-up dose 1 (Day 1) | ~$3,000.00 | Save thousand |
| Full weekly dose | ~$10,000.00 | Save ~$9,930/dose |
| Weekly dosing (monthly total) | ~$40,000+ | Save ~$39,930/mo |
| Every-2-week dosing | ~$20,000+/mo | Save ~$19,930/mo |
| Annual cost (typical) | ~$400,000+ | Save ~$399,000+/yr |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Talvey Prescription Program?
The Patient Assistance Program is free to apply for and provides Talvey at no medication cost if approved. But the process involves detailed applications, oncology-team coordination, prior-treatment documentation (4 prior lines including PI, IMiD, and anti-CD38), REMS-program enrollment, hospital-based step-up dosing coordination (to monitor for cytokine release syndrome), and ongoing renewal management. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Talvey:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $30,000–$45,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Talvey assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Talvey Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Talvey:
Talvey (talquetamab) is a first-in-class bispecific T-cell engager that targets GPRC5D on myeloma cells and CD3 on T cells, used to treat relapsed or refractory multiple myeloma in heavily pre-treated patients. It is given as a subcutaneous injection following a step-up dosing schedule (in a hospital setting initially) to manage cytokine release syndrome risk.
How Talvey Works:
Talvey is a bispecific antibody designed to treat multiple myeloma by simultaneously binding to GPRC5D on cancer cells and CD3 on T cells. This physical connection forces the patient’s own immune system to recognize and destroy the malignant cells through “redirected T-cell killing.” This innovative approach is highly effective for heavily pre-treated patients, often producing strong responses even after other advanced therapies have failed.
Form and use:
This medication is administered as a subcutaneous injection, beginning with a “step-up” dosing phase conducted in a hospital setting for safety monitoring. Once the initial phase is complete, maintenance doses are given either weekly or every two weeks at a weight-based concentration. The specific treatment schedule is individualized for each patient based on their clinical response and overall tolerability.
Generic availability:
As of 2026, there is no biosimilar version of Talvey available in the United States. While it remains a unique branded therapy, other advanced options for late-stage multiple myeloma exist, such as the bispecific antibodies Tecvayli and Elrexfio, or CAR-T cell therapies like Carvykti. The choice between these specialized treatments depends on the patient’s prior therapy history and clinical needs.
Warnings:
Talvey carries boxed warnings for cytokine release syndrome (CRS) and neurologic toxicity, which is why initial dosing requires hospital monitoring. Significant side effects can also include oral toxicities like taste changes and ulcers, skin rashes, weight loss, and serious infections. Patients must be closely counseled to recognize and immediately report any signs of CRS or neurological impairment to their healthcare team.
FAQ (Frequently Asked Questions)
How Much Does Talvey Cost Without Insurance?
The retail cost commonly runs $30,000–$45,000 per month, with annual costs reaching $400,000+. Through AffordMyPrescriptions, qualifying patients receive Talvey at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Talvey Different From Other Myeloma Therapies?
Talvey is a bispecific T-cell engager (BiTE) targeting GPRC5D — a different myeloma target from BCMA-directed therapies (Tecvayli, CAR-T like Carvykti and Abecma). Because Talvey targets a different surface marker, it can be effective in patients who have progressed on BCMA-directed therapies. The bispecific approach uses your own T cells to attack myeloma — similar to CAR-T but without the engineering and infusion logistics.
Why Are The First Doses Given In A Hospital?
Talvey can cause cytokine release syndrome (CRS) — an immune reaction with fever, low blood pressure, hypoxia, and other signs — most commonly during the first 1–2 doses. The step-up dosing schedule (smaller doses first) and hospital monitoring during these early doses help detect and manage CRS early. After successful step-up, ongoing dosing can be given in outpatient settings.
Are There Other Bispecifics Or CAR-T Therapies I Should Know About?
Talvey can cause cytokine release syndrome (CRS) — an immune reaction with fever, low blood pressure, hypoxia, and other signs — most commonly during the first 1–2 doses. The step-up dosing schedule (smaller doses first) and hospital monitoring during these early doses help detect and manage CRS early. After successful step-up, ongoing dosing can be given in outpatient settings.
Can I Get Talvey Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify for Talvey Patient Assistance, especially if you face specialty-tier copays you cannot afford. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If your initial application is denied, we explore alternatives — the manufacturer’s copay savings program if you have commercial insurance, independent foundations such as the International Myeloma Foundation, Multiple Myeloma Research Foundation, Leukemia & Lymphoma Society, PAN Foundation, or HealthWell Foundation, or asking your oncology team whether a different bispecific or CAR-T approach would be appropriate. If we cannot find a path, you will not be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Talvey, our team may be able to help you access assistance programs designed to make brand specialty multiple myeloma bispecific therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.